Advances in Treatment for Age-Related Macular Degeneration

SriniVas Sadda, MD; Caroline R. Baumal, MD


April 25, 2022

Age-related macular degeneration (AMD) occurs when aging causes damage to part of the retina, which can lead to loss of central vision. AMD is categorized as either dry or wet. Wet AMD is less common and develops in the later stage of disease, when abnormal blood vessels grow in the back of the eye and damage the macula.

Anti-VEGF injection therapy has been used to treat patients with wet AMD for nearly two decades.

In this ReCAP, Dr SriniVas Sadda, from University of California Los Angeles, and Dr Caroline Baumal, from Tufts Medical School, discuss the limitations of these treatments, including the frequency and number of injections required.

The doctors discuss the benefits of biosimilars and explain how ongoing research is leading to treatment options that require fewer office visits. They also outline how recently approved therapies — including the port delivery system, which is a surgically placed refillable ocular implant that continuously delivers ranibizumab into the vitreous — are already being implemented in clinical practice and changing the treatment landscape for patients with wet AMD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.